Achillion Pharmaceuticals Inc Has Bullish Trade, Samuel Isaly’s Orbimed Advisors Llc Bought Stake!

February 14, 2018 - By Winifred Garcia

 Achillion Pharmaceuticals Inc Has Bullish Trade, Samuel Isaly's Orbimed Advisors Llc Bought Stake!

Investors sentiment decreased to 0.96 in 2017 Q3. Its down 0.37, from 1.33 in 2017Q2. It dived, as 16 investors sold Achillion Pharmaceuticals, Inc. shares while 37 reduced holdings. 17 funds opened positions while 34 raised stakes. 105.14 million shares or 4.06% more from 101.03 million shares in 2017Q2 were reported.

Tudor Investment Corp Et Al holds 0.01% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) or 70,868 shares. Cwm Ltd Liability Co invested in 75 shares or 0% of the stock. Legal And General Gru Pcl reported 46,345 shares. Dekabank Deutsche Girozentrale stated it has 69,800 shares. 1.02 million were accumulated by Armistice Capital Limited Liability Company. Amalgamated Financial Bank holds 0% or 14,686 shares. The Ohio-based Meeder Asset Mgmt has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Secor Advsr L P holds 0.06% or 149,817 shares. Metropolitan Life Com accumulated 0% or 74,525 shares. Nj State Employees Deferred Compensation Plan invested in 30,000 shares. Proshare Ltd holds 85,073 shares or 0% of its portfolio. Geode Cap Management Limited Co invested in 1.04M shares or 0% of the stock. Morgan Stanley holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 516,501 shares. Eventide Asset Mgmt Ltd Llc invested 0.22% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Ameritas Investment Ptnrs owns 10,118 shares.

The New Samuel Isaly’s Orbimed Advisors Llc Holding in Achillion Pharmaceuticals Inc

Orbimed Advisors Llc reported SC 13G/A form with the SEC for Achillion Pharmaceuticals Inc. Access it here: 000117266118000508. As reported by Samuel Isaly’s Orbimed Advisors Llc, the filler owns 3.58% or 4,936,173 shares of the Health Care–company.

Achillion Pharmaceuticals Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Samuel Isaly’s Orbimed Advisors Llc’s positive view for Achillion Pharmaceuticals Inc. For a hedge fund managing $6.70 billion in assets and having 72+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Samuel Isaly’s Orbimed Advisors Llc’s portfolio is in the sector.

Achillion Pharmaceuticals Inc Institutional Sentiment

Filings show 135 investors own Achillion Pharmaceuticals Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 22381239. 128537804 were owned by these investors. 14 funds opened new Achillion Pharmaceuticals Inc stakes, 59 increased positions. There were 33 that closed positions and 38 reduced them.

4 investors had the stock in their top 10. Some are: Ra Capital Management Llc, Sarissa Capital Management Lp..

Turner Investments Lp is an investor bullish on Achillion Pharmaceuticals Inc, owning 1086000 shares as of Q3 2015 for 1.52% of its portfolio. Rtw Investments Llc owns 2551261 shares or 5.56% of its portfolio. MA Ra Capital Management Llc have 11.64% of its portfolio for 11733815 shares. Further, Dafna Capital Management Llc reported stake worth 3.29% of its portfolio. The CT Bourgeon Capital Management Llc owns 60700 shares. Achillion Pharmaceuticals Inc is 0.29% of its portfolio.

Business Profile

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

SEC Form 13G.

Samuel Isaly’s Orbimed Advisors Llc website.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on February, 22. They expect $-0.15 earnings per share, down 400.00 % or $0.12 from last year’s $-0.03 per share. After $-0.14 actual earnings per share reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.14 % negative EPS growth.

The stock increased 1.36% or $0.04 during the last trading session, reaching $2.98. About 1.33 million shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 47.61% since February 14, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $410.82 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 11 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Achillion Pharma has $16 highest and $3.5 lowest target. $6.44’s average target is 116.11% above currents $2.98 stock price. Achillion Pharma had 26 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Sell” rating given on Thursday, July 14 by Chardan Capital Markets. Robert W. Baird maintained it with “Hold” rating and $4.0 target in Monday, September 11 report. Leerink Swann maintained the stock with “Buy” rating in Friday, August 11 report. As per Monday, December 11, the company rating was maintained by Leerink Swann. Leerink Swann downgraded the stock to “Market Perform” rating in Friday, January 29 report. Maxim Group maintained the shares of ACHN in report on Wednesday, August 9 with “Buy” rating. The rating was initiated by Wedbush on Friday, September 23 with “Outperform”. FBR Capital initiated the shares of ACHN in report on Thursday, September 15 with “Outperform” rating. The firm has “Sell” rating given on Friday, September 23 by Chardan Capital Markets. Chardan Capital Markets upgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Friday, November 4. Chardan Capital Markets has “Neutral” rating and $5 target.

Another recent and important Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news was published by Globenewswire.com which published an article titled: “Achillion to Present at the Leerink Partners 7th Annual Global Healthcare …” on February 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: